阿布昔替尼治疗急性湿疹的临床疗效及对CC趋化因子27和胸腺基质淋巴生成素表达的影响  

Clinical efficacy of aboxitinib in the treatment of acute eczema and its influence on the expression of CC chemokine 27 and thymic stromal lymphopoietin

作　　者：胡悦 翟慧慧 施欢 HU Yue;ZHAI Hui-hui;SHI Huan(Department of Dermatology,Shanghai Dermatology Hospital,Shanghai 200443,China)

机构地区：[1]上海市皮肤病医院皮肤科,上海200443

出　　处：《临床和实验医学杂志》2024年第16期1787-1790,共4页Journal of Clinical and Experimental Medicine

基　　金：上海市皮肤病医院引进人才科研基金项目(编号:2021KYQD01)。

摘　　要：目的研究阿布昔替尼治疗急性湿疹的临床疗效及对患者血清CC趋化因子27(CCL27)、胸腺基质淋巴生成素(TSLP)表达的影响。方法研究方法为回顾性分析,以2022年12月至2023年12月入上海市皮肤病医院的110例急性湿疹患者为观察对象,按照治疗方式不同分为研究组(n=55)与对照组(n=55)。研究组联用氯雷他定、阿布昔替尼治疗,对照组单用氯雷他定治疗,两组患者均持续性治疗12周。比较两组患者的临床疗效,治疗前、治疗12周后的湿疹面积及严重度指数(EASI)评分、皮损瘙痒程度[视觉模拟评分法(VAS)评分]、血清中CCL27、TSLP水平、炎症因子[白细胞介素(IL)-6、IL-4]表达水平,并记录治疗过程中的药物安全性。结果研究组患者的治疗总有效率为94.55%,明显高于对照组(72.73%),差异有统计学意义(P<0.05)。治疗12周后,两组患者的EASI、VAS评分均较治疗前明显降低,且研究组EASI、VAS评分分别为(1.83±0.92)、(1.76±0.55)分,均显著低于对照组[(2.65±1.01)、(3.34±0.82)分],差异均有统计学意义(P<0.05)。治疗12周后,两组患者的血清CCL27、TSLP水平均较治疗前显著降低,且研究组的血清CCL27、TSLP水平分别为(98.72±8.57)pg/mL、(2.21±0.69)ng/mL,均显著低于对照组[(105.54±10.92)pg/mL、(2.56±0.66)ng/mL],差异均有统计学意义(P<0.05)。治疗12周后,两组患者的血清IL-4、IL-13水平均较治疗前显著降低,且研究组的血清IL-4、IL-13水平分别为(0.14±0.02)ng/L、(25.17±3.16)pg/L,均显著低于对照组[(0.35±0.08)ng/L、(27.43±4.12)pg/L],差异均有统计学意义(P<0.05)。治疗期间研究组仅有1例出现肝功能轻度升高,研究药量不变,未发展为严重不良事件,其余患者均未发生明显不适。结论与单纯氯雷他定治疗相比,阿布昔替尼联合氯雷他定治疗急性湿疹能够有效缓解患者各项临床症状与体征,减少皮损面积,改善皮损严重与瘙痒程度,降低血清内炎症因子及CCLObjective To study the clinical efficacy of abucicitinib in the treatment of acute eczema and its effect on the expression of serum CC chemokine 27(CCL 27)and thymic stromal lymphopoietin(TSLP)in patients.Methods A retrospective analysis was used on 110 patients with acute eczema admitted to Shanghai Dermatology Hospital from December 2022 to December 2023.They were divided into the study group(n=55)and the control group(n=55)according to different treatment methods.The study group was treated with loratadine and abucicitinib,and the control group was treated with loratadine alone.Patients in two groups were treated for 12 weeks.The clinical effects,and the eczema area and severity index(EASI)score,pruritus degree of skin lesions[visual analogue scale(VAS)score],serum levels of CCL 27 and TSLP,inflammatory factor expression level before treatment and after 12 weeks of treatment of the two groups were compared,and the drug safety of the two groups of patients during treatment was recorded.Results The overall response rate of patients in the study group was 94.55%,which was significantly higher than that in the control group(72.73%),and the difference was statistically significant(P<0.05).After 12 weeks of treatment,the EASI and VAS scores of the two groups were significantly lower than those before treatment,and the EASI and VAS scores of the study group were(1.83±0.92)and(1.76±0.55)points,respectively,which were significantly lower than those of the control group[(2.65±1.01)and(3.34±0.82)points],the differences were statistically significant(P<0.05).After 12 weeks of treatment,the levels of serum CCL27 and TSLP in the two groups were significantly lower than those before treatment,and the levels of serum CCL27 and TSLP in the study group were(98.72±8.57)pg/mL and(2.21±0.69)ng/mL,respectively,which were significantly lower than those in the control group[(105.54±10.92)pg/mL,(2.56±0.66)ng/mL],the differences were statistically significant(P<0.05).After 12 weeks of treatment,the levels of serum IL-4 and IL-1

关 键 词：湿疹 氯雷他定 趋化因子CCL27 阿布昔替尼 胸腺基质淋巴生成素 炎症因子 

分 类 号：R758.23[医药卫生—皮肤病学与性病学]